Protease-activated receptor-2 (PAR-2): Structure-function study of receptor activation by diverse peptides related to tethered-ligand epitopes

被引:48
|
作者
Maryanoff, BE [1 ]
Santulli, RJ [1 ]
McComsey, DF [1 ]
Hoekstra, WJ [1 ]
Hoey, K [1 ]
Smith, CE [1 ]
Addo, M [1 ]
Darrow, AL [1 ]
Andrade-Gordon, P [1 ]
机构
[1] RW Johnson Pharmaceut Res Inst, Drug Discovery, Spring House, PA 19477 USA
关键词
protease-activated receptor; agonist peptides; intracellular calcium; structure-activity; tethered-ligand receptor; transfected cells;
D O I
10.1006/abbi.2000.2207
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Protease-activated receptor-a (PAR-S) is a tethered-ligand, G-protein-coupled receptor that is activated by proteolytic cleavage or by small peptides derived from its cleaved N-terminal sequence, such as SLIGRL-NH2. To assess specific PAR activity, we developed an immortalized murine PAR-1 (-/-) cell line transfected with either human PAR-8 or PAR-1. A "directed" library of more than 100 PAR agonist peptide analogues was synthesized and evaluated for PAR-8 and PAR-1 activity to establish an in-depth structure-function profile for specific action on PAR-S. The most potent agonist peptides (EC50 = 2-4 muM) had Lys at position 6, Ala at position 4, and pFPhe at position 2; however, these also exhibited potent PAR-1 activity (EC50 = 0.05-0.35 muM). We identified SLIARK-NH2 and SL-Cha-ARL-NH2 as relatively potent, highly selective PAR-2 agonists with EC50 values of 4 muM. Position 1 did not tolerate basic, acidic, or large hydrophobic amino acids. N-Terminal capping by acetyl eliminated PAR-2 activity, although removal of the amino group reduced potency by just 4-fold. At position 2, substitution of Leu by Cha or Phe gave equivalent PAR-2 potency, but this modification also activated PAR-1, whereas Ala, Asp, Lys, or Gln abolished PAR-2 activity; at position 3, Re and Cha were optimal, although various amino acids were tolerated; at position 4, Ala or Cha increased PAR-2 potency 2-fold, although Cha introduced PAR-1 activity; at position 5, Arg or Lys could be replaced successfully by large hydrophobic amino acids. These results with hexapeptide C-terminal amides that mimic the native PAR-2 ligand indicate structural modes for obtaining optimal PAR-2 activity, which could be useful for the design of PAR-2 antagonists. (C) 2001 Academic Press.
引用
收藏
页码:195 / 204
页数:10
相关论文
共 30 条
  • [21] Stimulation of protease-activated receptor-2 inhibits airway eosinophilia, hyperresponsiveness and bronchoconstriction in a murine model of allergic inflammation
    De Campo, BA
    Henry, PJ
    BRITISH JOURNAL OF PHARMACOLOGY, 2005, 144 (08) : 1100 - 1108
  • [22] Effects of telmisartan on arterial vasodilation via protease-activated receptor-2 activation in SHRSP.Z-Leprfa/IzmDmcr rats with metabolic syndrome
    Kagota, S.
    Maruyama, K.
    Wakuda, H.
    McGuire, J. J.
    Yoshikawa, N.
    Nakamura, K.
    Shinozuka, K.
    CORONARY ARTERY DISEASE 2013, 2013, : 139 - 142
  • [23] The protease-activated receptor2 (PAR2)-prostaglandin E2-prostanoid EP receptor axis:: A potential bronchoprotective unit in the respiratory tract?
    Henry, PJ
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2006, 533 (1-3) : 156 - 170
  • [24] Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice
    Narita, Masato
    Hanada, Kenji
    Kawamura, Yosuke
    Ichikawa, Hiroaki
    Sakai, Shuntaro
    Yokono, Yoshikazu
    Senoo, Maiko
    Narita, Noritomo
    Shimada, Michiko
    Osanai, Tomohiro
    Okumura, Ken
    Tomita, Hirofumi
    HYPERTENSION RESEARCH, 2021, 44 (10) : 1261 - 1273
  • [25] Rivaroxaban attenuates cardiac hypertrophy by inhibiting protease-activated receptor-2 signaling in renin-overexpressing hypertensive mice
    Masato Narita
    Kenji Hanada
    Yosuke Kawamura
    Hiroaki Ichikawa
    Shuntaro Sakai
    Yoshikazu Yokono
    Maiko Senoo
    Noritomo Narita
    Michiko Shimada
    Tomohiro Osanai
    Ken Okumura
    Hirofumi Tomita
    Hypertension Research, 2021, 44 : 1261 - 1273
  • [26] Differential effects of β-arrestins on the internalization, desensitization and ERK1/2 activation downstream of protease activated receptor-2
    Kumar, P.
    Lau, C. S.
    Mathur, M.
    Wang, P.
    DeFea, K. A.
    AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY, 2007, 293 (01): : C346 - C357
  • [27] Deficiency of protease-activated receptor (PAR) 1 and PAR2 exacerbates collagen-induced arthritis in mice via differing mechanisms
    Xue, Meilang
    Lin, Haiyan
    Liang, Hai Po Helena
    McKelvey, Kelly
    Zhao, Ruilong
    March, Lyn
    Jackson, Christopher
    RHEUMATOLOGY, 2021, 60 (06) : 2990 - 3003
  • [28] Protease-activated receptor (PAR) 1 but not PAR2 or PAR4 mediates endothelium-dependent relaxation to thrombin and trypsin in human pulmonary arteries
    Hamilton, JR
    Moffatt, JD
    Frauman, AG
    Cocks, TM
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2001, 38 (01) : 108 - 119
  • [29] Protease-activated receptor 2 (PAR2) upregulates granulocyte colony stimulating factor (G-CSF) expression in breast cancer cells
    Carvalho, Erika
    de Almeida, Vitor Hugo
    Rondon, Araci M. R.
    Possik, Patricia A.
    Viola, Joao P. B.
    Monteiro, Robson Q.
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 504 (01) : 270 - 276
  • [30] Protease-activated receptor 1 and 2 contribute to angiotensin II-induced activation of adventitial fibroblasts from rat aorta
    He, Rui-Qing
    Tang, Xiao-Feng
    Zhang, Sao-Li
    Li, Xiao-Dong
    Hong, Mo-Na
    Chen, Qi-Zhi
    Han, Wei-Qing
    Gao, Ping-Jin
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2016, 473 (02) : 517 - 523